Categories
Change Password!
Reset Password!
NO derivatives of NSAIDs safely impacts metabolism of
osteoblasts and therefore can be utilized for bone disorders like high-turnover
osteoporosis in post-menopausal women.
A
recent study published in “Life sciences” journal demonstrated the safer
influence of NO-NSAIDs in comparison to Aspirin, Naproxen and Celecoxib.
NO-NSAIDs showed inhibitory action towards proteinases which was related to
osteoid degradation.
Dr
Maria Cristina Aisa and colleagues conducted a study on NO-releasing
non-selective NSAIDs. The NSAIDs are the class of drugs best known for their
role in alleviating pain and are used post-traumatically/post-operatively to
obtain analgesia. However, this class of drugs may restrain repair and
remodelling of bones.
Dr Aisa and colleagues selected two NCX-4016
and HCT-3012, NO-derivatives of Aspirin and Naproxen (NSAIDs) and evaluated
their role on osteoblasts in comparison to parent compounds and Celecoxib
(COX-2-selective inhibitor). The study involved proliferation, early and late
differentiation of MG-63 osteoblast-like cells along with its degradation via
proteinases, a necessary step of remodelling). The role of drugs was evaluated
at every stage.
Both NO-NSAIDs did not affect osteoblasts
proliferation and differentiation as their parent compounds Aspirin, Naproxen
and Cox inhibitor, Celecoxib. Depletion in metalloproteinases, cathepsin B and
plasminogen (devastating bone enzymes) activity was observed. Also, the
NO-donor sodium nitroprusside showed inhibitory role towards proteinases and
reflected positive effect towards bone growth and remodelling.
Life Sciences
COX inhibitors and bone: A safer impact on osteoblasts by NO-releasing NSAIDs
Maria Cristina Aisa et al.
Comments (0)